GLA
ABCL icon

Good Life Advisors’s AbCellera Biologics ABCL Stock Holding History

Good Life Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$46K – 437
2023
Q3 		$46K Buy
+10,000
New +$60.8K 0.01% 410

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Good Life Advisors's ABCL Position: Q4 2023 in Review

Good Life Advisors sold out of AbCellera Biologics (ABCL) in Q4 2023, closing a stake of 10,000 shares — an estimated $46K sold.

Good Life Advisors first reported a position in ABCL in Q3 2023 and held it in 1 quarter. The position peaked at $46K in Q3 2023. 142 funds tracked by Wall St. Rank hold ABCL as of Q4 2023.

  • Good Life Advisors reported no remaining AbCellera Biologics position as of Q4 2023 after selling out during the quarter.
  • Good Life Advisors sold 10,000 AbCellera Biologics shares in Q4 2023, an estimated $46K.
  • Good Life Advisors first reported a position in AbCellera Biologics in Q3 2023 and held it in 1 quarter.
  • Good Life Advisors's AbCellera Biologics position peaked at $46K in Q3 2023.
  • 142 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2023.

Based on Good Life Advisors's 13F filing for Q4 2023, filed 18 Jan 2024.